Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007

Annals of the Rheumatic Diseases

Volumn 66, Issue SUPPL. 3, 2007, Pages

  Furst, D E ^a   Breedveld, F C ^b   Kalden, J R ^c   Smolen, J S ^d   Burmester, G R ^e   Sieper, J ^e   Emery, P ^f   Keystone, E C ^g   Schiff, M H ^h   Mease, P ⁱ   Van Riel, P L C M ^j   Fleischmann, R ^k   Weisman, M H ^l   Weinblatt, M E ^m  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f UNIVERSITY OF LEEDS   (United Kingdom)

^g MOUNT SINAI HOSPITAL   (Canada)

^h Denver Arthritis Clinic PC   (United States)

ⁱ Seattle Rhumatology Associates   (United States)

^j RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^k UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^l Cedars Sinai Hospital   (United States)

^m BRIGHAM AND WOMEN S HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEFACEPT; ALPHA INTERFERON; AZATHIOPRINE; CYCLOPHOSPHAMIDE; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RIBAVIRIN; RITUXIMAB; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANKYLOSING SPONDYLITIS; APLASTIC ANEMIA; BACTERIAL INFECTION; BEHCET DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CROHN DISEASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUSTRY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERITIS; GIANT CELL ARTERITIS; HEALTH CARE ORGANIZATION; HEPATITIS; HEPATITIS C; HUMAN; INFECTION; INJECTION SITE REACTION; INTERVERTEBRAL DISK HERNIA; JUVENILE RHEUMATOID ARTHRITIS; LEUKOENCEPHALOPATHY; LONG TERM CARE; LUNG CANCER; LUNG DISEASE; LUPUS VULGARIS; LYMPHOMA; META ANALYSIS; MONOTHERAPY; NEUROLOGIC DISEASE; NONHODGKIN LYMPHOMA; PANCYTOPENIA; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; PYODERMA GANGRENOSUM; QUALITY OF LIFE; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SJOEGREN SYNDROME; SKIN CANCER; SPONDYLOARTHROPATHY; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT RESPONSE; TUBERCULOSIS; ULCERATIVE COLITIS; VASCULITIS; WEGENER GRANULOMATOSIS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS; ARTHRITIS, JUVENILE RHEUMATOID; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNOCONJUGATES; INTERLEUKIN-1; NEOPLASMS; SPONDYLITIS, ANKYLOSING; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 35649016260     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.081430     Document Type: Conference Paper

References (523)

1. Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Bijlsma JW, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases. Ann Rheum Dis 2004;65(Suppl 2):ii2-15.
2. Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: developing guidelines. BMJ 1999;318:593-6.
3. Wolfe F, Pincus T, O'Dell J. Evaluation and documentation of rheumatoid arthritis disease status in the clinic: which variables best predict change in therapy. J Rheumatol 2001;28:1712-7.
4. Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003;42:244-57.
5. Gladman DD, Helliwell P, Mease PJ, Nash P, Ritchlin C, Taylor W. Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum 2004;50:24-35.
6. Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Grassnickel L, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003;48:1667-75.
7. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187-93.
8. Davis Jr JC, Van Der HD, Braun J, Dougados M, Cush J, Clegg DO, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230-6.
9. Gorman JD, Sack KE, Davis Jr JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002;346:1349-56.
10. Van Den BF, Kruithof E, Baeten D, Herssens A, de KF, Mielants H, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 2002;46:755-65.
11. Agarwal SK, Maier AL, Chibnik LB, Coblyn JS, Fossel A, Lee R, et al. Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical center. Arthritis Rheum 2005;53:872-8.
12. Bang LM, Keating GM. Adalimumab: a review of its use in rheumatoid arthritis. BioDrugs 2004;18:121-39.
13. Breedveld FC, Emery P, Keystone E, Patel K, Furst DE, Kalden JR, et al. Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 2004;63:149-55.
14. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van VR, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
15. Culy CR, Keating GM. Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis. Drugs 2002;62:2493-537.
16. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993;36:1681-90.
17. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 1994;344:1125-7.
18. Fleischmann RM, Iqbal I, Stern RL. Considerations with the use of biological therapy in the treatment of rheumatoid arthritis. Expert Opin Drug Saf 2004;3:391-403.
19. Furst DE, Keystone E, Maini RN, Smolen JS. Recapitulation of the round-table discussion: assessing the role of anti-tumour necrosis factor therapy in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 1999;38(Suppl 2):50-3.
20. Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003;30:2563-71.
21. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002;46:1443-50.
22. Harriman G, Harper LK, Schaible TF. Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFalpha treatment. Ann Rheum Dis 1999;58(Suppl 1):161-4.
23. Hyrich KL, Symmons DP, Watson KD, Silman AJ. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:1786-94.
24. Jones RE, Moreland LW. Tumor necrosis factor inhibitors for rheumatoid arthritis. Bull Rheum Dis 1999;48:1-4.
25. Kavanaugh AF. Anti-tumor necrosis factor-alpha monoclonal antibody therapy for rheumatoid arthritis. Rheum Dis Clin North Am 1998;24:593-614.
26. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400-11.
27. Klareskog L, Van Der HD, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81.
28. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
29. Mariette X, Malalse MG, Rainer F, et al. Adalimumab (Humira) is effective and safe with different traditional concomitant DMARDS in treating rheumatoid arthritis in real-life clinical practice: a full-set analysis of the REACT trial. ARD 2006;65(Suppl 11):FR10144.
30. Mariette X. ReAct Trial. Ann Rheum Dis 2007;64:1382.
31. Markham A, Lamb HM. Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 2000;59:1341-59.
32. Pavelka K. Adalimumab in the treatment of rheumatoid arthritis. Aging Health 2006;2:533-45.
33. Scheinfeld N. Adalimumab (HUMIRA): a review. J Drugs Dermatol 2003;2:375-7.
34. Smolen JS, Han C, Bala M, Maini RN, Kalden JR, Van Der HD, et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 2005;52:1020-30.
35. St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50:3432-43.
36. van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508-16.
37. Weaver AL, Lautzenheiser RL, Schiff MH, Gibofsky A, Perruquet JL, Luetkemeyer J, et al. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry. Curr Med Res Opin 2006;22:185-98.
38. van der Heijde D, Kivitz A, Schiff MH, et al. Treatment with adalimumab reduces signs and symptoms and induces partial remission in patients with Ankylosing Spodylitis: 1 year results from ATLAS. Arthritis & Rheumatism 2006;54(Suppl):s792 (abs 2017).
39. van Vollenhoven R, Cullinane Carli C, Bratt J, et al. Patients treated with TNFA antagonists increase their participation in the work-force: potential for significant long-term indirect cost gains. EULAR SAT02200. 2006.
40. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279-89.
41. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264-72.
42. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-90.
43. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 2006;33:712-21.
44. Kavanaugh A, Antoni C, Mease P, Gladman D, Yan S, Bala M, et al. Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis. J Rheumatol 2006;33:2254-9.
45. Antoni C, Krueger GG, de VK, Birbara C, Beutler A, Guzzo C, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;64:1150-7.
46. Kavanaugh A, Krueger GG, Beutler A, Guzzo C, Zhou B, Dooley LT, et al. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 2007;66:498-505.
47. Gladman DD, Mease PJ, Ritchlin CT, Choy EH, Sharp JT, Ory PA, et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum 2007;56:476-88.
48. Heiberg MS, Kaufmann C, Rodevand E, Mikkelsen K, Koldingsnes W, Mowinckel P, et al. The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6-month results from a longitudinal, observational, multicenter study. Ann Rheum Dis 2007;66:1038-42.
49. Sattar N, Crompton P, Cherry L, Kane D, Lowe G, McInnes IB. Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: a double-blind, placebo-controlled study. Arthritis Rheum 2007;56:831-9.
50. Kimball AB, Jackson JM, Sobell JM, Boh EE, Grekin S, Pharmd EB, et al. Reductions in healthcare resource utilization in psoriatic arthritis patients receiving etanercept therapy: results from the educate trial. J Drugs Dermatol 2007;6:299-306.
51. Baeten D, Kruithof E, Van Den BF, Van den BN, Herssens A, Mielants H, et al. Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis 2003;62:829-34.
52. Brandt J, Haibel H, Reddig J, et al. Anti-TNF alpha treatment of patients with severe anklyosing spondylitis: a one year follow-up. Arthritis Rheum 2000;44(Suppl):S403.
53. Brandt J, Kavenaugh AF, Listing J, et al. Six months results of a German double-blind placebo controlled Phase III clinical trial in active ankylosing spondylitis. Arthritis Rheum 2004;46:S429.
54. Braun J, Pham T, Sieper J, Davis J, van der LS, Dougados M, Van Der HD. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003;62:817-24.
55. Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, et al. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 2005;64:229-34.
56. Schiff M, Kavanaugh A, Weisman M, Segurado O. Safety and efficacy of more than 4 years of adalimumab therapy in rheumatoid arthritis. Annual Meeting of the American Academy of Dermatology, New Orleans. 18 February 2005.
57. Haibel H, Rudwaleit M, Brandt HC, Grozdanovic Z, Listing J, Kupper H, et al. Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. Arthritis Rheum 2006;54:678-81.
58. Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpatrick SB, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:889-94.
59. Bansback N, Booner A, Marra C, et al. A review of economic evaluations in ankylosing spondylitis: considerations and proposal for an omeract reference case. EULAR THU0528 2006.
60. Cummins C, Connock M, Fry-Smith A, Burls A. A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept. Health Technol Assess 2002:1-43.
61. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342:763-9.
62. Lovell DJ, Giannini EH, Reiff A, Jones OY, Schneider R, Olson JC, et al. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum 2003;48:218-26.
63. Baert F, Noman M, Vermeire S, Van AG, D' HG, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8.
64. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9.
65. Sandborn W, Rachmilewitz D, Hanauer S, et al. Infliximab induction and maintenance therapy for ulcerative colitis: the Act 2 Trial. AGA Abstracts 2007;688:A104.
66. Rutgeerts P, Feagan BG, Olsen A, et al. A randomized placebo-controlled trial of infliximab therapy for active ulcerative coiltis: Act 1 Trial. AGA Abstracts 2007;689:A105.
67. Sfikakis PP, Markomichelakis NN, Alpsoy E, Assaad-Khalil S, Bodaghi B, Gul A, et al. Anti-TNF therapy in the management of Behcet's disease: review and basis for recommendations. Rheumatology (Oxford) 2007;46:736-41.
68. Zein NN. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005;42:315-22.
69. Brooklyn TN, Dunnill MG, Shetty A, Bowden JJ, Williams JD, Griffiths CE, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 2006;55:505-9.
70. Kavaru M, duBois RM, Costabel U, et al. Chest x-ray assessment using a detailed scoring method in a randomized trail of infliximab in subjects with chronic pulmonary sarcoidosis. Chest 2007;128(4):203s.
71. Mariette X, Ravaud P, Steinfeld S, Baron G, Goetz J, Hachulla E, et al. Inefficacy of infliximab in primary Sjogren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren's Syndrome (TRIPSS). Arthritis Rheum 2004;50:1270-6.
72. Sankar V, Brennan MT, Kok MR, Leakan RA, Smith JA, Manny J, et al. Etanercept in Sjogren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum 2004;50:2240-5.
73. Steinfeld SD, Demols P, Salmon I, Kiss R, Appelboom T. Infliximab in patients with primary Sjogren's syndrome: a pilot study. Arthritis Rheum 2001;44:2371-5.
74. Steinfeld SD, Demols P, Salmon I, Kiss R, Appelboom T. Infliximab in patients with primary Sjogren's syndrome: a pilot study. Arthritis Rheum 2001;44:2371-5.
75. Cohen S, Shoup A, Weisman MH, Harris J. Etanercept treatment for autoimmune inner ear disease: results of a pilot placebo-controlled study. Otol Neurotol 2005;26:903-7.
76. van der Vaart H, Koeter GH, Postma DS, Kauffman HF, ten Hacken NH. First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172:465-9.
77. Karppien J, Korhonen T, Paimela L, et al. The efficacy of infliximab for disc herniation-induced sciatica. A 1-year follow-up of first 2, a randomised controlled trial. OASIS 2007;159:1383.
78. Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007;146:621-30.
79. Salvarani C, Macchioni P, Manzini C, Paolazzi G, Trotta A, Manganelli P, et al. Infliximab plus prednisone or placebo plusprednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. Ann Intern Med 2007;146:631-9.
80. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
81. Combe B, C. C.F.U.e.a. Double-blind comparison of etanercept and sulphasalazine alone and combined in patients with active RA. Arthritis Rheum 2007;46(Suppl):S519.
82. Jarvis B, Faulds D. Etanercept: a review of its use in rheumatoid arthritis. Drugs 1999;57:945-66.
83. Moreland LW, Margolies G, Heck Jr LW, Saway A, Blosch C, Hanna R, et al. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol 1996;23:1849-55.
84. Burmester GR, van de Putte LB, Rau P, et al. Long term efficacy and safety of adalimumab monotherapy in patients with DMARD-refractory RA: results from a two year study. Arthritis Rheum 2002;46(Suppl): S537.
85. Cohen G, Courvoisier N, Cohen JD, Zaltni S, Sany J, Combe B. The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. Clin Exp Rheumatol 2005;23:795-800.
86. Guis S, Balfour I, Bowyer SL, et al. 308 A/G polymorphism in the tumor necrosis factor alpha gene influences outcome of etanercept treatment in rheumatoid arthritis (RA). OASIS 2007.
87. Van der Laken CJ, Vujevich J, de Jager JP, et al. Imaging and serum analysis of complex formation of radiolabeled infliximab and anti-infliximab in responders and non-responders to treatment of rheumatoid arthritis. OASIS 2007.
88. Buch MH, Seto Y, Bingham SJ, Bejarano V, Bryer D, White J, et al. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept. Arthritis Rheum 2005;52:42-8.
89. Furst DE, et al. PULSE study. [accepted abstract] ACR/ARHP Annual Scientific Meeting, Boston MA. 2007.
90. Furst DE, et al. PULSE study, [accepted abstract] ACR/ARHP Annual Scientific Meeting, Boston MA. 2007.
91. Johnson AK, Schiff MH, Mease PJ, et al. Comparison of 2 Doses of Etanercept (50 vs 100 mg) in Active RA: A Randomized Double Blind Study. J Rheumatol 2006;33:659-64.
92. van Vollenhoven RF, Brannemark S, Klareskog L. Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect. Ann Rheum Dis 2004;63:426-30.
93. Keystone E, Kavanaugh AF, Sharp JT, et al. Adalimumab, a fully human anti-TNF-alpha monoclonal antibody, inhibits the progression of structural joint damage in patients with active RA despite concomitant methotrexate therapy. Arthritis Rheum 2002;46(Suppl):S205.
94. Hochberg MC, Tracy JK, Hawkins-Holt M, Flores RH. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 2003;62(Suppl 2):ii13-6.
95. Maksymowych WP, Mallon C, Spady B, Peerani R. Alberta Capital Health region studies in rheumatoid arthritis prospective observational inception cohort: efficacy, adverse events and withdrawal. Arthritis Rheum 2001;44(Suppl):S82.
96. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594- 602.
97. Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:27-35.
98. Genovese MC, Mease P, Thomson GT, Kivitz AJ, Perdok RJ, Weinberg MA, et al. Safety and efficacy of adalimumab in the treatment of patients with Psoriatic Arthritis who had failed disease-modifying antirheumatic drug therapy. J Rheumatol 2007;34:1040-50.
99. Boehncke WH, Prinz J, Gottlieb AB. Biologic therapies for psoriasis. A systematic review. J Rheumatol 2006;33:1447-51.
100. Cassell S, Kavanaugh AF. Therapies for psoriatic nail disease. A systematic review. J Rheumatol 2006;33:1452-6.
101. Gladman DD, Mease PJ. Towards international guidelines for the management of psoriatic arthritis. J Rheumatol 2006;33:1228-30.
102. Cauza E, Spak M, Cauza K, Hanusch-Enserer U, Dunky A, Wagner E. Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab. Rheumatol Int 2002;22:227-32.
103. Helliwell PS. Therapies for dactylitis in psoriatic arthritis. A systematic review. J Rheumatol 2006;33:1439-41.
104. Kavanaugh AF, Ritchlin CT. Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J Rheumatol 2006;33:1417-21.
105. Nash P. Therapies for axial disease in psoriatic arthritis. A systematic review. J Rheumatol 2006;33:1431-4.
106. Ritchlin CT. Therapies for psoriatic enthesopathy. A systematic review. J Rheumatol 2006;33:1435-8.
107. Soriano ER, McHugh NJ. Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J Rheumatol 2006;33:1422-30.
108. Strober BE, Siu K, Menon K. Conventional systemic agents for psoriasis. A systematic review. J Rheumatol 2006;33:1442-6.
109. de Gannes GC, Ghoreishi M, Pope J, Russell A, Bell D, Adams S, et al. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007;143:223-31.
110. Delaunay C, Farrenq V, Marini-Portugal A, Cohen JD, Chevalier X, Claudepierre P. Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data. J Rheumatol 2005;32:2183-5.
111. Gibbs A, Gogarty M, Veale D, et al. Efficacy of anakinard (Kineret) in psoriatic arthritis, a clinical and immunohistological study. Ann Rheum Dis 2006;65(Suppl II):ii65-216.
112. Papp K, Mease P, Garovoy M, et al. Efalizumab in patients with psoriatic arthritis: results of a phase II randomized double-blind placebo controlled study. J Cutan Med Surg 2006;11:57-66.
113. Mease PJ, Gladman DD, Keystone EC. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2006;54:1638-45.
114. Davis JC, Van Der HD, Dougados M, Woolley JM. Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy. Arthritis Rheum 2005;53:494-501.
115. Braun J, Davis J, Dougados M, et al. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:316- 20.
116. Braun J, Landewe R, Hermann KG, Han J, Yan S, Williamson P, et al. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 2006;54:1646-52.
117. Rudwaleit M, Baraliakos X, Listing J, Brandt J, Sieper J, Braun J. Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept. Ann Rheum Dis 2005;64:1305-10.
118. Hyrich KL, Silman AJ, Watson KD, Symmons DP. Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis 2004;63:1538-43.
119. Keystone EC. Safety of biologic therapies: an update. J Rheumatol 2005;74(Suppl):8-12.
120. Khonna D, McMahon M, Furst DE. Safety of tumour necrosis factor-alpha antagonists. Drug Saf 2004;27:307-24.
121. Bassard P, Kezouh A, Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clinical Infectious Diseases 2006;43:717-22.
122. Ruderman EM, Markenson JA. Granulomatous infections and tumor necrosis factor antagonist therapies: update through June 2002. Arthritis Rheum 2003;48(Suppl 9).
123. Furst DE, Wallis R, Broder M, Beenhouwer DO. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum 2006;36:159-67.
124. Mohan AK, Cote TR, Block JA, Manadan AM, Siegel JN, Braun MM. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 2004;39:295-9.
125. Wallis RS, Broder M, Wong J, Beenhouwer D. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis 2004;39:1254-5.
126. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004;38:1261-5.
127. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
128. Saliu OY, Sofer C, Stein DS, Schwander SK, Wallis RS. Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J Infect Dis 2006;194:486-92.
129. Centers for Disease Control and Prevention. Tuberculosis associated with blocking agents against tumor necrosis factor-alpha: California, 2002-2003. MMWR Morb Mortal Wkly Rep 2004;53:683-6.
130. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, Montera D, Pascual-Gomez E, Mola EM, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005;52:1766- 72.
131. Perez JL, Kupper H, Spencer-Green G. Impact of screening for latent TB prior to initiating ANTI-TNF therapy in North America and Europe. [abstract] EULAR Ann Rheum Dis 2005. Fri OPOCB.
132. Winthrop KL, Siegel JN, Jereb J, Taylor Z, Iademarco MF. Tuberculosis associated with therapy against tumor necrosis factor alpha. Arthritis Rheum 2005;52:2968-74.
133. Cummins C, Connock M, Fry-Smith A, Burls A. A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept. Health Technol Assess 2002;6:1-43.
134. Bargstrom L, Yocum D, Tesser J, et al. Coccidiomycosis (Valley Fever) occurring during infliximab therapy. Arthritis Rheum 2004;46:s169.
135. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46:2287-93.
136. Elkayam O, Caspi D, Reitblatt T, Charboneau D, Rubins JB. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 2004;33:283-8.
137. Filler SG, Yeaman MR, Sheppard DC. Tumor necrosis factor inhibition and invasive fungal infections. Clin Infect Dis 2005;41(Suppl 3):S208-12.
138. Garrison L, McDonnell ND. Etanercept: therapeutic use in patients with rheumatoid arthritis. Ann Rheum Dis 1999;58(Suppl 1):165-9.
139. Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002;46:2565-70.
140. Manadan AM, Block JA, Sequeira W. Mycobacteria tuberculosis peritonitis associated with etanercept therapy. Clin Exp Rheumatol 2003;21:526.
141. Slifman NR, Gershon SK, Lee JH, Edwards ET, Braun MM. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum 2003;48:319-24.
142. Jain VV, Evans T, Peterson MW. Reactivation histoplasmosis after treatment with anti-tumor necrosis factor alpha in a patient from a nonendemic area. Respir Med 2006;100:1291-3.
143. Listing J, Strangefeld A, Rau R, et al. Infections in RA patients treated with infliximab or etanercept. Ann Rheum Dis 2005;54:433.
144. Salliot C, Gossec L, Ruyssen-Witrand A, Luc M, Duclos M, Guignard S, et al. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology (Oxford) 2007;46:327-34.
145. Jacobsson LT, Turesson C, Gulfe A, et al. No increase of severe infections in RA patients treated with TNF-blockers. OASIS 2007.
146. Westhovens R, Yocum D, Han J, Berman A, Strusberg I, Geusens P, Rahman MU. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum 2006;54:1075-86.
147. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:2368-76.
148. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 2006;54:628-34.
149. Weinblatt M, Combe B, White A, et al. Safety of abatacept in patients with active rheumatoid arthritis receiving background non-biologic DMARDs: 1 year results of the ASSURE Trial. Ann Rheum Dis 2005;64:60.
150. Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004;50:1412-9.
151. Kapetanovic MC, Saxne T, Nilsson JA, Geborek P. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatology (Oxford) 2007;46:608-11.
152. Fomin I, Caspi D, Levy V, Varsano N, Shalev Y, Paran D, et al. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis 2006;65:191-4.
153. Lequerre T, Vittecoq O, Klemmer N, Goeb V, Pouplin S, Menard JF, et al. Management of infusion reactions to infliximab in patients with rheumatoid arthritis or spondyloarthritis: experience from an immunotherapy unit of rheumatology. J Rheumatol 2006;33:1307-14.
154. Augustsson J, Eksborg S, Ernestam S, Gullstrom E, van Vollenhoven RF. Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis (RA). Ann Rheum Dis. Published Online First: 16 August 2007. doi: 10.1136/ard.2007. 070771.
155. Boecklund E, Ekbom A, Sparen P, Feltelius N, Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 1998;317:180-1.
156. Geborek P, Bladstrom A, Turesson C, Gulfe A, Petersson IF, Saxne T, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005;64:699-703.
157. Prior P, Symmons DP, Hawkins CF, Scott DL, Brown R. Cancer morbidity in rheumatoid arthritis. Ann Rheum Dis 1984;43:128-31.
158. Bongartz T, Harle P, Friedrich S, Karrer S, Vogt T, Seitz A, et al. Successful treatment of psoriatic onycho-pachydermo periostitis (POPP) with adalimumab. Arthritis Rheum 2005;52:280-2.
159. Okada SK, Siegal JN. Anti-TNF antibody therapy in RA and risk of serious infections and malignancies. JAMA 2006;296:2201-2.
160. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005;64:1421-6.
161. Setoguchi S, Solomon DH, Avorn J, Katz J, Weinblatt M, Glynn R, et al. Use of anti-TNF alpha drugs and incidence of hematologic and solid cancers in patients with rheumatoid arthritis. Arthritis Rheum 2005;52(Suppl).
162. Rennard SI, Fogarty C, Kelson SI, et al. The safety and efficancy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:926-34.
163. Stone JH, Holbrook JT, Marriott MA, Tibbs AK, Sejismundo LP, Min YI, et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum 2006;54:1608-18.
164. Watson KD, Dixon WG, Hyrich KL, et al. Influences of Anti-TNF therapy and previous malignancy on cancer incidence in patients with rheumatoid arthritis (RA): Result from the BSR biologics register. EULAR 2006 June:21-24, Amsterdam.
165. Cush J, Spiera R. Etanercept update on "dear doctor" safety letter. Amer College of Rheum. Hotline. Nov 2002.
166. Anker SD, Coats AJ. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 2002;86:123-30.
167. Khanna D, McMahon M, Furst DE. Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here? Arthritis Rheum 2004;50:1040-50.
168. Tam L, Li E, Tomlinson B. Effects of infliximab treatment on insulin sensitivity and lipid profile in patients with active rheumatoid arthritis (RA). OASIS 2007;879:181.
169. Jacobsson LT, Turesson C, Nilsson J, et al. Treatment with TNF-blockers is associated with reduced premature mortality in patients with rheumatoid arthritis. EULAR 21-24 June 2006, Amsterdam 2006.
170. Martin L, Barr S, Green F, Fritzler M. Severe fatal complications associated with infliximab therapy in rheumatoid arthritis. J Rheumatol 2006;33:2.
171. Ostor AJ, Chilvers ER, Somerville MF, Lim AY, Lane SE, Crisp AJ, et al. Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis. J Rheumatol 2006;33:622-8.
172. Cacoub P, Lidove O, Maisonobe T, Duhaut P, Thibault V, Ghillani P, et al. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 2002;46:3317-26.
173. Esteve M, Saro C, Gonzalez-Huix F, Suarez F, Forne M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004;53:1363-5.
174. Ince A, Rusche W, Daud U, Ross SC, Weiss TD, Moore TL, et al. Etanercept in the treatment of rheumatoid arthritis patients with chronic hepatitis C infection. Ann Rheum Dis 2002;61(Supp 1):191.
175. Khanna M, Shirodkar MA, Gottlieb AB. Etanercept therapy in patients with autoimmunity and hepatitis C. J Dermatolog Treat 2003;14:229-32.
176. Naveau S, Chollet-Martin S, Dharancy S, Mathurin P, Jouet P, Piquet MA, et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 2004;39:1390-7.
177. Oniankitan O, Duvoux C, Challine D, Mallat A, Chevalier X, Pawlotsky JM, et al. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol 2004;31:7-109.
178. Smith KJ, Skelton H. Common variable immunodeficiency treated with a recombinant human IgG, tumour necrosis factor-alpha receptor fusion protein. Br J Dermatol 2001;144:597-600.
179. Millonig G, Kern M, Ludwiczek O, Nachbaur K, Vogel W. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? World J Gastroenterol 2006;12:974-6.
180. Blum E, Katz J. Infliximab therapy and LFT abnormalities in patients with Crohn's disease. AGA Abstracts 2007:A659-660.
181. Schiemann U, Kellner H. [Gastrointestinal side effects in the therapy of rheumatologic diseases]. Z Gastroenterol 2002;40:937- 43.
182. Wendling D, Auge B, Bettinger D, Lohse A, Le HG, Bresson-Hadni S, et al. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis 2005;64:788-9.
183. Roux' CH, Brocq O, Breuil V, Albert C, Euller-Ziegler L. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy. Rheumatology (Oxford) 2007;46:695-8.
184. Vesga L, Terdiman JP, Mahadevan U. Adalimumab use in pregnancy. Gut 2005;54:890.
185. Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lichtenstein GR. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 2004;99:2385-92.
186. Antoni CE, Furst DE, Manger B, et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease or rheumatoid arthritis. Arthritis Rheum 2001;44(Suppl):S152.
187. Chambers CD, Johnson DL, Jones KL. Pregnancy outcome in women exposed to anti-TNF-alpha medications: The OTIS Rheumatoid Arthritis in Pregnancy Study. [abstract] ARD EULAR 2007;66(sup II):THUR0162.
188. Chambers CD, Johnson DL, Jones KL. Adalimumab and pregnancy outcome: The OTIS Autoimmune Diseases in Pregnancy Project. The OTIS Collaborative Research Group University of San Diego. Amer Acad Derm 2007;56(2):AB10.
189. Joven BE, Garcia-Gonzalez AJ, Ruiz T, et al. Pregnancy in women receiving anti-TNF-alpha therapy. Experience in Spain. OASIS, 2007 Pres;884:Poster 186.
190. Ostensen M. Etanercept in breast milk. Letter to the Editor. J Rheumatol 2004;31:1017-18.
191. Allanore Y, Sellam J, Batteux F, Job DC, Weill B, Kahan A. Induction of autoantibodies in refractory rheumatoid arthritis treated by infliximab. Clin Exp Rheumatol 2004;22:756-8.
192. Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond RH, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004;2:542-53.
193. Chadha T, Hernandez JE. Infliximab-related lupus and associated valvulitis: a case report and review of the literature. Arthritis Rheum 2006;55:163-6.
194. Pallotta P, Cianchini G, Ruffelli M, Puddu P. Infliximab-induced lupus-like reaction in a patient with psoriatic arthritis. Rheumatology (Oxford) 2006;45:116-7.
195. Perez-Garcia C, Maymo J, Lisbona Perez MP, Almirall BM, Carbonell AJ. Drug-induced systemic lupus erythematosus in ankylosing spondylitis associated with infliximab. Rheumatology (Oxford) 2006;45:114-6.
196. Bingham SJ, Barcelos A, Buch M, et al. Induction of serological lupus in patients on leflunomide and infliximab. Arthritis Rheum 2002;46(Suppl):S168.
197. Christopher L, Wigley F. TNF-alpha antagonists induce lupus-like syndrome in patients with scleroderma and polyarthritis. Arthritis Rheum 2002;46(Suppl):S358.
198. De RL, Kruithof E, Van DN, Hoffman IE, Van den BN, Van Den BF, et al. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum 2003;48:1015-23.
199. Eriksson C, Engstrand S, Sundqvist KG, Rantapaa-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis 2005;64:403-7.
200. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001;44:2862-9.
201. Jarand J, Zochodne DW, Martin LO, Voll C. Neurological complications of infliximab. J Rheumatol 2006;33:1018-20.
202. Shin IS, Baer AN, Kwon HJ, Papadopoulos EJ, Siegel JN. Guillain-Barre and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy. Arthritis Rheum 54:1429-34.
203. Ruppert M, De CL, van OJ, Hubens G, Balliu L, Vaneerdeweg W. Intestinal necrosis in a patient with rheumatoid arthritis receiving anti-TNF treatment. Acta Chir Belg 2006;106:225-7.
204. Whiting-O'Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991;90:711-6.
205. Bresnihan B. The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis. Semin Arthritis Rheum 2001;30:17-20.
206. Bresnihan B, Newmark R, Robbins S, Genant HK. Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-week randomized, placebo-controlled trial. J Rheumatol 2004;31:1103-11.
207. Fleischmann RM, Schechtman J, Bennett R, Handel ML, Burmester GR, Tesser J, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHulL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. Arthritis Rheum 2003;48:927-34.
208. Fleischmann RM, Tesser J, Schiff MH, Schechtman J, Burmester GR, Bennett R, et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:1006-12.
209. Fleischmann R, Stern R, Iqbal I. Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis. Expert Opin Biol Ther 2004;4:1333-44.
210. Schiff MH. Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade: comment on the article by Buch et al. Arthritis Rheum 2005;52:364-5.
211. Haibel H, Rudwaleit M, Listing J, Sieper J. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis 2005;64:296-8.
212. Tan AL, Marzo-Ortega H, O'Connor P, Fraser A, Emery P, McGonagle D. Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann Rheum Dis 2004;63:1041-5.
213. Chevalier X, Mugnier B, Bouvenot G. [Targeted anti-cytokine therapies for osteoarthritis]. Bull Acad Natl Med 2006;190:1411- 20.
214. Chevalier X, Giraudeau B, Conrozier T, Marliere J, Kiefer P, Goupille P. Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. J Rheumatol 2005;32:1317-23.
215. Moosig F, Zeuner R, Renk C, Schroder J. IL-1RA in refractory systemic lupus erythematosus. Lupus 2004;13:605.
216. Ostendorf B, Iking-Konert C, Kurz K, Jung G, Sander O, Schneider M. Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann Rheum Dis 2005;64:630-3.
217. Handwerger B, Kafka S, Dhillon G, Thomson G, Dunn M, Ferbas J, et al. Effects of Anakinra (KINERET) on vaccine response in patients with rheumatoid arthritis. Annual Meeting of the American College of Rheumatology, San Antonio, Texas, USA, No. 1477, 16 October 2004.
218. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353:1114-23.
219. Kramer JM, Genant HK, Moreland LW, Russell AS, Emery P, Bud-Mendoza C, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006;144:865-76.
220. Kremer JM, Westhovens R, Leon M, Di GE, Alten R, Steinfeld S, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003;349:1907-15.
221. Kremer JM, Dougados M, Emery P, Durez P, Sibilia J, Shergy W, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:2263-71.
222. Moreland LW, Alten R, Van Den BF, Appelboom T, Leon M, Emery P, et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 2002;46:1470-9.
223. Schiff M, Pritchard C, Teng J, et al. The safety of Abatacept in patients with active RA and inadequate response to anti-TNF therapy: results from the ARRIVE trial. [abstract] ARD EULAR 2007:OP0212.
224. Genovese MC, Schiff M, Luggen M, et al. Sustained efficacy and safety through two years in patients with RA in the long term extension of the ATTAIN trial. Arthritis & Rheum 2006;54:s244:498.
225. Kramer J, Westhovens R, Russell A, et al. Long-term efficacy of abatecept through 2 years of treatment in rheumatoid arthritis patients in the AIM Trial. Arthritis Rheum 2006;54(Suppl 9):s247.
226. Abrams JR, Lebwohl MG, Guzzo CA, Jegasothy BV, Goldfarb MT, Goffe BS, et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999;103:1243-52.
227. Lovell D, Ruperto N, Prieur A, et al. Assessment of open label co-stimulation blockade with abatacept in children and adolescents with active juvenile idiopathic arthritis (JIA). Arthritis Rheum 2006;54(Suppl 9):s326.
228. Moreland LW, Combe B, Steinfeld S, et al. An integrated safety analysis of abatacept in the treatment of rheumatoid arthritis (RA) across patient types and background therapies. Ann Rheum Dis Eular, 2006;65(Supp 11), 110.
229. Simon T, Smitten A, Franklin J, et al. Malignancies in RA abatacept clinical development program and updated epidemiological assessment. ARD EULAR 2007 66;sup II; Fri OP0124.
230. Emery P, Fleischman RM, Filipowicz-Sosnowska A, et al. Rituximab in rheumatoid arthritis: a double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2005;52:1917.
231. Emery P, Sheeran T, Lehane PB, Saiedabadi N, Shaw TM. Efficacy and safety of rituximab at 2 years following a single treatment in patients with active rheumatoid arthritis. Arthritis Rheum 2004;50(Suppl 9):S659.
232. Keystone EC, Burmester GR, Furie R, Loveless JE, Emery P, Cravets MW, et al. Improved auality of life with rituximab plus methotrexate in patients with active rheumatoid arthritis who experienced inadequate response to one or more anti-TNF-alpha therapies. Arthritis Rheum 2005;52:287.
233. Fleischmann R, Racewicz A, Schechtman J, et al. Rituximab efficacy in rheumatoid arthritis is independent of coadministration of glucocorticoids: Results from the Dose-ranging Assessment iNternational Clinical Evaluation of Rituximab in rheumatoid arthritis (DANCER) Study. Arthritis Rheum 2005;52:263.
234. van Vollenhoven R, Schechtman J, Szczepanski L, Fleischmann R, Hazleman BL, Nash P, et al. Safety and tolerability of rituximab in patients with moderate to severe rheumatoid arthritis (RA): results from the Dose-ranging Assessment international Clinical Evaluation of Rituximab in RA (DANCER) study. Arthritis Rheum 2005;52:263.
235. van Vollenhoven R, Emery P, Fleischmann RM, Filipowicz-Sosnowska A, Szczepanski L, Racewicz A, et al. Safety and tolerability of rituximab in patients with moderate to severe rheumatoid arthritis (RA): results from the Dose-ranging Assessment iNternational Clinical Evaluation of Rituximab in RA (DANCER) study. Ann Rheum Dis 2005;64(Suppl 3):432.
236. Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 2001;40:205-11.
237. Emery P, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Edwards JC, Magrini F, et al. Sustained efficacy at 48 weeks after single treatment course of rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2003;48:S439.
238. Breedveld FC, Agarwal SK, Yin M, Ng C, et al. Relationship between clinical response rituximab pharmacokinetics and peripheral B cell levels in Rheumatoid Arthritis. EULAR 2006 THU 0207.
239. Breedveld FC, Genovese MC, Emery P, et al. Safety of TNF inhibitors in rheumatoid arthritis patients previously treated with rituximab. EULAR 2006 THU 0206.
240. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIb double-blind, placebocontrolled, dose-ranging trial. (DANCER). Arthritis Rheum 2006;54:1390-00.
241. Cohen SB, Greenwald M, Dougados MR, Emery P, Furie R, Shaw TM, et al. Efficacy and safety of rituximab in active RA patients who experienced an inadequate response to one or more anti-TNF-alpha therapies. Arthritis Rheum 2005;52:1830.
242. Looney RJ. B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritis. Rheumatology (Oxford) 2005;44(Suppl 2):ii13-7.
243. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81.
244. Shaw T, Quan J, Totoritis MC. B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience. Ann Rheum Dis 2003;62(Suppl 2):ii55-9.
245. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie R, Genovese M, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum 2006;54:2793-806.
246. Tsutsumi Y, Kanamori H, Mori A, Tanaka J, Asaka M, Imamura M, et al. Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Saf 2005;4:599-608.
247. Huffstutter J, Sienknechet C. Resistant adult still's disease treated with infliximab: a report of two cases. Arthritis Rheum 2002;46(Suppl):S326.
248. Kraetsch HG, Antoni C, Kalden JR, Manger B. Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences. Ann Rheum Dis 2001;60(Suppl 3):iii55-7.
249. Fernandez-Nebro A, Tomero E, Ortiz-Santamaria V, Castro MC, Olive A, de HM, et al. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists. Am J Med 2005;118:552-6.
250. Elkayam O, Hawkins PN, Lachmann H, Yaron M, Caspi D. Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum 2002;46:571-2573.
251. Gottenberg JE, Merle-Vincent F, Bentaberry F, Allanore Y, Berenbaum F, Fautrel B, et al. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy. Arthritis Rheum 2003;48:2019-24.
252. Ortiz-Santamaria V, Vals-Roc M, Sanmarti M, et al. Treatment of secondary amyloidosis with infliximab. Arthritis Rheum 2002;46(Suppl):S71.
253. Tomero E, Carmona L, Gonzalez I, et al. Infliximab in secondary amyloidosis complicating inflammatory arthropathies. Arthritis Rheum 2002;46:S70.
254. Smith GR, Tymms KE, Falk M. Etanercept treatment of renal amyloidosis complicating rheumatoid arthritis. Intern Med J 2004;34:570-2.
255. Robinson ND, Guitart J. Recalcitrant, recurrent aphthous stomatitis treated with etanercept. Arch Dermatol 2003;139:1259- 62.
256. Vujevich J, Zirwas M. Treatment of severe, recalcitrant, major aphthous stomatitis with adalimumab. Cutis 2005;76:129-32.
257. Atzeni F, Sarzi-Puttini P, Capsoni F, Mecchia M, Marrazza MG, Carrabba M. Successful treatment of resistant Behcet's disease with etanercept. Clin Exp Rheumatol 2005;23:729.
258. Sakellariou GT, Chatzigiannis I, Tstouridis I. Infliximab infusions for presistent back pain in two patients with Schmorl's nodes. Rheumatology 2005;44:1588-90.
259. Genevay S, Stingelin S, Gabay C. Efficacy of etanercept in the treatment of acute, severe sciatica: a pilot study. Ann Rheum Dis 2004;63:1120-3.
260. Estrach C, Mpofu S, Moots RJ. Efficacy and safety of infliximab and adalimumab in Behcet's syndrome. Annual Scientific Meeting, American College of Rheumatology, Orlando, USA. 25 October 2003.
261. Gulli S, Arrigo C, Bocchino L, Morgante L, Sangari D, Castagna I, et al. Remission or Behcet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report. BMC Musculoskelet Disord 2003;4:19.
262. Hassord PV, Binder SW, Nelson V, Vasiliauskas EA. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behcet's disease: a case report. Gastroenterology 2001;120:995-9.
263. Licata G, Pinto A, Tuttolomondo A, Banco A, Ciccia F, Ferrante A, et al. Anti-tumour necrosis factor alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behcet's syndrome. Ann Rheum Dis 2003;62:280-1.
264. Magliocco MA, Gottlieb AB. Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J Am Acad Dermatol 2004;51:580-4.
265. Morrillas-Arques P, Callejas J, Iglesias-Jimenez E, et al. Etanercept/adalimumab in the treatment of Behcet's syndrome. Ann Rheum Dis 2006;65(Suppl II):374.
266. Rozenbaum M, Rosner I, Portnoy E. Remission of Behcet's syndrome with TNFalpha blocking treatment. Ann Rheum Dis 2002;61:283-4.
267. Saulsbury FT, Mann JA. Treatment with infliximab for a child with Behcet's disease. Arthritis Rheum 2003;49:599-600.
268. Sangle S, Hughes G, D'Cruz D. Infliximab in the management of resistant systemic vasculitus: poor response and significant adverse effects. OASIS 2007.
269. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet 2001;358:295-6.
270. Sfikakis PP. Behcet's disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis 2002;61(Suppl 2):ii51-3.
271. Ribi C, Sztajzel R, Delavelle J, Chizzolini C. Efficacy of TNF {alpha} blockade in cyclophosphamide resistant neuro-Behcet disease. J Neurol Neurosurg Psychiatry 2005;76:1733-5.
272. Sweiss NJ, Welsch MJ, Curran JJ, Ellman MH. Tumor necrosis factor inhibition as a novel treatment for refractory sarcoidosis. Arthritis Rheum 2005;53:788-91.
273. van Laar JA, Missotten T, van Daele PL, Jamnitski A, Baarsma GS, van Hagen PM. Adalimumab: a new modality for Behcet's disease? Ann Rheum Dis 2007;66:565-6.
274. Cortot AB, Cottin V, Miossec P, Fauchon E, Thivolet-Bejui F, Cordier JF. Improvement of refractory rheumatoid arthritis-associated constrictive bronchiolitis with etanercept. Respir Med 2005;99:511-4.
275. Spahr L, Rubbia-Brandt L, Frossard JL, Giostra E, Rougemont AL, Pugin J, et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J Hepatol 2002;37:448-55.
276. Menon KV, Stadheim L, Kamath PS, Wiesner RH, Gores GJ, Peine G, et al. A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol 2004;99:255-60.
277. Tsimberidou AM, Giles FJ, Duvic M, Kurzrock R. Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas. J Am Acad Dermatol 2004;51:200-4.
278. Cortis E, De BF, Insalaco A, Cioschi S, Muratori F, D'Urbano LE, et al. Abnormal production of tumor necrosis factor (TNF): alpha and clinical efficacy of the TNF inhibitor etanercept in a patient with PAPA syndrome [corrected]. J Pediatr 2004;145:851-5.
279. Cummins DL, Hiatt KM, Mimouni D, Vander Kolk CA, Cohen BA, Nousari CH. Generalized necrobiosis lipoidica treated with a combination of split-thickness autografting and immunomodulatory therapy. Int J Dermatol 2004;43:852-4.
280. Cusack C, Buckley C. Etanercept: effective in the management of hidradenitis suppurativa. Br J Dermatol 2006;154:726-9.
281. Zeichner JA, Stern DWK, Lebwohl M. Intralesional etanercept for the treatment of necrobiosis lipoidica. Washington DC: Annual Meeting of the American Academy of Dermatology, 6 February, 2004.
282. Hengstman G, van den Hoogen F, ven Engelen B, et al. Anti-TNF blockade with infliximab (Remicade) in polymyositis and dermatomyositis. Arthritis Rheum 2000;43(Suppl):S193.
283. Miller M, Mendez E, Klein-Gitelman M, Pachman L. Use of etanercept in juvenile dermatomyositis. Arthritis Rheum 2002;46(Suppl):S306.
284. Sprott H, Glatzel M, Michel BA. Treatment of myositis with etanercept (Enbrel), a recombinant human soluble fusion protein of TNF-alpha type II receptor and IgG1. Rheumatology (Oxford) 2004;43:524-6.
285. Nzeusseu A, Durez P, Houssiau F. Successful use of infliximab in a case of refractory juvenile dermatomyositis. Arthritis Rheum 2001;44(Suppl):S90.
286. Saadeyh C. Etanercept is effective in the treatment of polymyositis/dermatomyositis which is refractory to conventional therapy. Arthritis Rheum 2000;43(Suppl):S193.
287. Norman R, Greenberg RG, Jackson JM. Case reports of etanercept in inflammatory dermatoses. J Am Acad Dermatol 2006;54:S139-42.
288. Ortego-Centeno N, Callejas-Rubio JL, Sanchez-Cano D, Caballero-Morales T. Refractory chronic erythema nodosum successfully treated with adalimumab. J Eur Acad Dermatol Venereol 2007;21:408-10.
289. Takada K, Aksentijevich I, Mahadevan V, Dean JA, Kelley RI, Kastner DL. Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum 2003;48:2645-51.
290. Ozgocmen S, Ozcakar L, Ardicoglu O, Kocakoc E, Kaya A, Kiris A. Familial Mediterranean fever responds well to infliximab: single case experience. Clin Rheumatol 2006;25:83-7.
291. Ghavami A, Genevay S, Fulpius T, Gabay C. Etanercept in treatment of Felly's syndrome. Ann Rheum Dis 64:1090-1.
292. Andonopoulos AP, Meimaris N, Daoussis D, Bounas A, Giannopoulos G. Experience with infliximab (anti-TNF alpha monoclonal antibody) as monotherapy for giant cell arteritis. Ann Rheum Dis 2003;62:1116.
293. Cantini F, Niccoli L, Salvarani C, Padula A, Olivieri I. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum 2001;44:2933-5.
294. Tan AL, Holdsworth J, Pease C, Emery P, McGonagle D. Successful treatment of resistant giant cell arteritis with etanercept. Ann Rheum Dis 2003;62:373-4.
295. Ahmed MM, Mubashir E, Hayat S, Fowler M, Berney SM. Treatment of refractory temporal arteritis with adalimumab. Clin Rheumatol 2007;26:1353-5.
296. Wolff D, Roessler V, Steiner B, Wilhelm S, Weirich V, Brenmoehl J, et al. Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept. Bone Marrow Transplant 2005;35:1003-10.
297. Uberti JP, Ayash L, Ratanatharathorn V, Silver S, Reynolds C, Becker M, et al. Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease. Biol Blood Marrow Transplant 2005;11:680-7.
298. Kennedy GA, Butler J, Western R, Morton J, Durrant S, Hill GR. Combination antithymocyte globulin and soluble TNFalpha inhibitor (etanercept) +/-mycophenolate mofetil for treatment of steroid refractory acute graft-versus-host disease. Bone Marrow Transplant 2006;37:1143-7.
299. Chiang KY, Abhyankar S, Bridges K, Godder K, Henslee-Downey JP. Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease. Transplantation 2002;73:665-7.
300. Pavletic SZ, Klassen LW, Pope R, O'Dell JR, Traynor AE, Haire CE, et al. Treatment of relapse after autologous blood stem cell transplantation for severe rheumatoid arthritis. J Rheumatol 2001;64(Suppl):28-31.
301. Andolina M, Rabusin M, Maximova N, Di LG. Etanercept in graft-versus-host disease. Bone Marrow Transplant 2000;26:929.
302. Paridaens D, van de Bosch F, van der Loos TL, Krenning EP, van Hagen PM. The effect of etanercept on Graves ophthalmopathy: a pilot study. Eye 2005;19:1286-9.
303. McMinn Jr JR, Cohen S, Moore J, Lilly S, Parkhurst J, Tarantino MD, et al. Complete recovery from refractory immune thrombocytopenic purpura in three patients treated with etanercept. Am J Hematol 2003;73:135-40.
304. Peterson JR, Hsu FC, Simkin PA, Wener MH. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 2003;62:1078-82.
305. Pritchard C. Etanercept and hepatitis C. J Clin Rheumtol 1999;5:179.
306. Moreno E, Erra A, Leon Y, et al. Safety of etanercept treatment in patients with hepatitis B or C virus, and rheumatoid arthritis or ankylosing spondylitis. Ann Rheum Dis Eular 2004, FRI0106. [abstract].
307. Parke Fa, Reveville JD. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infections. Arthritis & Rheum 2004;51:800-4.
308. Marotte H, Fontanges E. Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus. Rheumatology (Oxford) 2007;46:97-9.
309. Rokhsar C, Rabhan N, Cohen SR. Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis, and concomitant hepatitis C infection. J Am Acad Dermatol 2006;54:361-2.
310. Wallis RS, Kyambadde P, Johnson JL, Horter L, Kittle R, Pohle M, et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS 2004;18:257-64.
311. Lin JH, Liebhaber M, Roberts RL, Dyer Z, Stiehm ER. Etanercept treatment of cutaneous granulomas in common variable immunodeficiency. J Allergy Clin Immunol 2006;117:878-82.
312. Cepeda E, Williams F, Ishimori M, Weisman M. The use of anti-tumor necrosis factor therapy in HIV positive individuals with rheumatic disease. Arthritis Rheum 2007;66(Suppl 1):5123-4.
313. Barohn RJ, Herbelin L, Kissel JT, King W, McVey AL, Saperstein DS, et al. Pilot trial of etanercept in the treatment or inclusion-body myositis. Neurology 2006;66:S123-4.
314. Singh R, Cuchacovich R, Huang W, Espinoza LR. Inclusion body myositis unresponsive to etanercept. J Clin Rheumatol 2001;7:279-80.
315. Olivieri I, Scarano E, Gigliotti P, Giasi V, Padula A. Successful treatment of juvenile-onset HLA-B27-associated severe and refractory heel thesitis with adalimumab documented by magnetic reasonance imaging. Rheumatology (Oxford) 2006;45:1315-7.
316. Weiss JE, Eberhard BA, Chowdhury D, Gottlieb BS. Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol 2004;31:808-10.
317. Burns JC, Mason WH, Hauger SB, Janai H, Bastian JF, Wohrley JD, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr 2005;146:662-7.
318. Lovelace K, Loyd A, Adelson D, Crowson N, Taylor JR, Cornelison R. Etanercept and the treatment of multicentric reticulohistiocytosis. Arch Dermatol 2005;141:1167-8.
319. Matejicka C, Morgan GJ, Schlegelmilch JG. Multicentric reticulohistiocytosis treated successfully with an anti-tumor necrosis factor agent: comment on the article by Gorman et al. Arthritis Rheum 2003;48:864-6.
320. Kovach BT, Calamia KT, Walsh JS, Ginsburg WW. Treatment of multicentric reticulohistiocytosis with etanercept. Arch Dermatol 2004;140:919-21.
321. Birnbaum AJ, Gentile P. Treatment of myelodysplasia in a patient with active rheumatoid arthritis. Ann Intern Med 2000;133:753-4.
322. Deeg HJ, Gotlib J, Beckham C, Dugan K, Holmberg L, Schubert M, et al. Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study. Leukemia 2002;16:162-4.
323. Rosenfeld C, Bedell C. Pilot study of recombinant human soluble tumor necrosis factor receptor (TNFR:Fc) in patients with low risk myelodysplastic syndrome. Leuk Res 2002;26:721-4.
324. Raza A, Dutt D, Dean L, et al. Combination of thalidomide and embrel for the treatment of patients with myelodysplastic syndromes (MDS). Blood 2001;98:273b.
325. Maciejewski JP, Risitano AM, Sloand EM, Wisch L, Geller N, Barrett JA, et al. A pilot study of the recombinant soluble human tumour necrosis factor receptor (p75)-Fc fusion protein in patients with myelodysplastic syndrome. Br J Haematol 2002;117:119-26.
326. Athreya B, Doughty R, Kastner D, et al. Periodic fever syndrome in children. Arthritis Rheum 2000;43(Suppl):S117.
327. Kroot EJ, Kraan MC, Smeets TJ, Maas M, Tak PP, Wouters JM. Tumour necrosis factor alpha blockade in treatment resistant pigmented villonodular synovitis. Ann Rheum Dis 2005;64:497-9.
328. Adams AB, Kazim M, Lehman TJ. Treatment of orbital myositis with adalimumab (Humira). J Rheumatol 2005;32:1374-5.
329. Carter JD. Treatment of relapsing polychondritis with a TNF antagonist. J Rheumatol 2005;32:1413.
330. Ehresman G. Infliximab in the treatment of polychondritis. Arthritis Rheum 2002;46(Suppl):S170.
331. Fonder MA, Cummins DL, Ehst BD, Anhalt JH. Adalimumab therapy for recalcitrant pyoderma gangrenosum. J Burns Wounds 2006;5:e8.
332. Heffernan MP, Anadkat MJ, Smith DI. Adalimumab treatment for pyoderma gangrenosum. Arch Dermatol 2007;143:306-8.
333. Magnano MD, Chakravarty EF, Broudy C, Chung L, Kelman A, Hillygus J, et al. A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the hands. J Rheumatol 2007;34:1323-7.
334. Sweiss N, Curran J, Ellman N. TNF-inhibition as a novel treatment for refractory sarcoidosis. Annual Scientific Meeting, American College of Rheumatology, Orlando, USA. 25 October 2003.
335. Callejas-Rubio JL, Ortego-Centeno N, Lopez-Perez L, Benticuaga MN. Treatment of therapy-resistant sarcoidosis with adalimumab. Clin Rheumatol 2006;25:596-7.
336. Korhonen T, Karppinen J, Malmivaara A, Autio R, Niinimaki J, Paimela L, et al. Efficacy of infliximab for disc herniation-induced sciatica: one-year follow-up. Spine 2004;29:2115-9.
337. Korhonen T, Karppinen J, Paimela L, Malmivaara A, Lindgren KA, Jarvinen S, et al. The treatment of disc herniation-induced sciatica with infliximab: results of a randomized, controlled, 3-month follow-up study. Spine 2005;30:2724-8.
338. Lam K, Woods A, Hummers K, Wigley F. Efficacy and safety of etanercept in scleroderma joint disease. Arthritis Rheum 2005;52:S588.
339. Pasternock FR, Fox LP, Engler DE. Silicone granulomas treated with etanercept. Arch Dermatol 2005;141:13-5.
340. Tobinick E, Davoodifar S. Efficacy of etanercept delivered by perispinal administration for chronic back and/or neck disc-related pain: a study of clinical observations in 143 patients. Curr Med Res Opin 2004;20:1075-85.
341. Khanna D, Liebling MR, Louie JS. Etanercept ameliorates sarcoidosis arthritis and skin disease. J Rheumatol 2003;30:1864- 7.
342. Utz JP, Limper AH, Kalra S, Specks U, Scott JP, Vuk-Pavlovic Z, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003;124:177-85.
343. Wagner AD, Andresen J, Jendro MC, Hulsemann JL, Zeidler H. Sustained response to tumor necrosis factor alpha-blocking agents in two patients with SAPHO syndrome. Arthritis Rheum 2002;46:1965-8.
344. Moul DK, Korman NJ. Severe hidradenitis suppurativa treated with adalimumab. Arch Dermatol 142:1110-2.
345. Heffernan MP, Smith DI. Adalimumab for treatment of cutaneous sarcoidosis. Arch Dermatol 2006;142:17-9.
346. Querfeld C, Bachmann P, Guitart J. The effectiveness of etanercept in treating cutaneous sarcoidosis. A case report. Amer Acad Derm 2007;50(suppl 1):P55.
347. Hobbs K. Chronic sarcoid arthritis treated with intraarticular etanercept. Arthritis Rheum 2005;52:987-8.
348. Ellman MH, MacDonald PA, Hayes FA. Etanercept treatment for diffuse scleroderma: a pilot study. Arthritis Rheum 2000;43(Suppl) :S392.
349. Bosello S, De SM, Tolusso B, Zoli A, Ferraccioli G. Tumor necrosis factor-alpha inhibitor therapy in erosive polyarthritis secondary to systemic sclerosis. Ann Intern Med 2005;143:918-20.
350. Zandbelt MM, de WP, van DP, Hoyng CB, van de PL, van den HF. Etanercept in the treatment of patients with primary Sjogren's syndrome: a pilot study. J Rheumatol 2004;31:96-101.
351. Pessler F, Monash B, Rettig P, Forbes B, Kreiger PA, Cron RQ. Sjogren syndrome in a child: favorable response of the arthritis to TNFalpha blockade. Clin Rheumatol 2006;25:746-8.
352. Fautrel B, Sibilia J, Mariette X, Combe B. Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases. Ann Rheum Dis 2005;64:262-6.
353. Stern A, Riley R, Buckley L. Worsening of macrophage activation syndrome in a patient with adult onset Still's disease after initiation of etanercept therapy. J Clin Rheumatol 2001;7:252-6.
354. Asherson RA, Pascoe L. Adult onset Still's disease: response to Enbrel. Ann Rheum Dis 2002;61:859-60.
355. Kumari R, Uppal SS. Prolonged remission in adult-onset Still's disease with etanercept. Clin Rheumatol 2006;25:106-8.
356. Gindi V, Lowe NJ, Koo S, Yamauchi PA. Treatment of Sweet's syndrome with the tumor necrosis factor antagonist etanercept in a patient with coexisting rheumatoid arthritis. Annual Meeting of the American Academy of Dermatology, New Orleans, USA. 18 February 2005.
357. Yamauchi PS, Turner L, Lowe NJ, Gindi V, Jackson JM. Treatment of recurrent Sweet's syndrome with coexisting rheumatoid arthritis with the tumor necrosis factor antagonist etanercept. J Am Acad Dermatol 2006;54:S122-6.
358. Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 2004;50:3161-9.
359. Lurati A, Teruzzi B, Salmaso A, et al. Macrophage activation syndrome (MAS) during anti-IL-1 receptor therapy (anakinra) in a patient affected by systemic onset idiopathic juvenile arthritis (soJIA): a report and review of the literature. Pediatr Rheumatol Online J 2007;3(2):79-85.
360. Lurati A, Teruzzi B, Salmaso A, et al. Macrophage activation syndrome (MAS) during anti-IL-1 receptor therapy (anakinra) in a patient affected by systemic onset idiopathic juvenile arthritis (soJIA): a report and review of the literature. Pediatr Rheumatol Online J 2007;3(2):79-85.
361. Hernandez-Ibarra H, Gutierrez L, Juarez S, et al. Prevalence, burden of illness and factors associated with neurocognitive dysfunction in Mexican patients with systemic lupus erythematous. Annual Scientific Meeting, American College of Rheumatology, Orlando, USA, No 378. 25 October 2003.
362. Principi M, Di LA, Ingrosso M, Pisani A, Marangi S, Amoruso A, et al. Lupus nephritis improvement after anti-tumor necrosis factor alpha monoclonal antibody (infliximab) treatment far Crohn's disease: a case report. Immunopharmacol Immunotoxicol 2004;26:243-8.
363. Hoffman GS, Merkel PA, Brasington RD, Lenschow DJ, Liang P. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 2004;50:2296-304.
364. Della RA, Tavoni A, Merlini G, Baldini C, Sebastiani M, Lombardi M, et al. Two Takayasu arteritis patients successfully treated with infliximab: a potential disease-modifying agent? Rheumatology (Oxford) 2005;44:1074-5.
365. Tato F, Rieger J, Hoffmann U. Refractory Takayasu's arteritis successfully treated with the human, monoclonal anti-tumor necrosis factor antibody adalimumab. Int Angiol 2005;24:304-7.
366. Hull KM, Drewe E, Aksentijevich I, Singh HK, Wong K, McDermott EM, et al. The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine (Baltimore) 2002;81:349-68.
367. Lamprecht P, Moosig F, dam-Klages S, Mrowietz U, Csernok E, Kirrstetter M, et al. Small vessel vasculitis and relapsing panniculitis in tumour necrosis factor receptor associated periodic syndrome (TRAPS). Ann Rheum Dis 2004;63:1518-20.
368. Drewe E, McDermott EM, Powell RJ. Treatment of the nephrotic syndrome with etanercept in patients with the tumor necrosis factor receptor-associated periodic syndrome. N Engl J Med 2000;343:1044- 5.
369. Joseph A, Raj D, Dua HS, Powell PT, Lanyon PC, Powell RJ. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology 2003;110:1449-53.
370. Smith JA, Thompson DJ, Whitcup SM, Suhler E, Clarke G, Smith S, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 2005;53:18-23.
371. Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etercept. Arthritis Rheum 2005;52:2447-51.
372. Foster CS, Tufail F, Waheed N, et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 2003;121:437-40.
373. Biester S, Deuter C, Michels H, Haefner R, Kuemmerle-Deschner J, Doycheva D, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 2007;91:319-24.
374. Foeldvari I, Nielsen S, Kummerle-Deschner J, Espada G, Horneff G, Bica B, et al. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol 2007;34:1146-50.
375. Vazquez-Cobian LB, Flynn T, Lehman TJ. Adalimumab therapy for childhood uveitis. J Pediatr 2006;149:572-5.
376. Reiff A, Takei S, Sadeghi S, et al. Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 2007;44:1411-5.
377. Schmeling H, Horneff G. Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology (Oxford) 2005;44:1008- 11.
378. Guignard S, Gossec L, Salliot C Ruy, Ruyssen-Witrand A, Luc M, Duclos M, et al. Efficacy of rumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis 2006;65:1631-4.
379. Booth A, Harper L, Hammad T, Bacon P, Griffith M, Levy J, et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 2004;15:717-21.
380. Feinstein J, Arroyo R. Successful treatment of childhood onset refractory polyarteritis nodosa with tumor necrosis factor alpha blockade. J Clin Rheumatol 2005;11:219-22.
381. van der Bijl AE, Allaart CF, Van VJ, Van DS, Breedveld FC. Rheumatoid vasculitis treated with infliximab. J Rheumatol 2005;32:1607-9.
382. Saji T, Kemmotsu Y. Infliximab for Kawasaki syndrome. J Pediatr 2006;149:426.
383. Arbach O, Gross WL, Gause A. Treatment of refractory Churg-Strauss-syndrome (CSS) by TNF-a blockade. Immunobiology 2002;206:495-501.
384. Gause AM, Arbach O, Reinhold-Keller E, et al. Induction of remission with infliximab in active generalized Wegener's granulomatosis is effective but complicated by severe infections. Annual Scientific Meeting, American College of Rheumatology, Orlando, USA No.450. 25 October 2003.
385. Emsley HC, Smith CJ, Georgiou RF, Vail A, Hopkins SJ, Rothwell NJ, et al. A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J Neurol Neurosurg Psychiatry 2005;76:1366-72.
386. Leslie KS, Lachmann HJ, Bruning E, McGrath JA, Bybee A, Gallimore JR, et al. Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch Dermatol 2006;142:1591-7.
387. Rudinskaya A, Trock D. Successful treatment of a patient with refractory adult-onset Still disease with anakinra. J Clin Rheumatol 2003;9:330-2.
388. Quartier P, Lequerre T, Rosellini D, et al. Anakinra in systemic-onset juvenile idiopathic arthritis and adult onset Still's disease. EULAR OP0174 2007.
389. Aelion JA, Odhav SK. Prompt responses to treatment with anakinra in adult onset Stills disease. EULAR FRI0109 2004.
390. Haraoui B, Bourrelle D, Kaminska E. Anakinra in the treatment of adult-onset Still's disease. EULAR FRI0148 2007.
391. Kalliolias GD, Georgiou PE, Antonopolus IA. Anakinra (AKR) Anakinra treatment in patients with adult-onset Still's disease is fast, effective, safe and steroid sparing:experience from and uncontrolled trial. Ann Rheum Dis 2007;66:842-3.
392. Nordstrom D, Aarnio M, Helve T, et al. Favorable response to anakinra in refractory adult-onset Still's disease. A clinical study is needed. ACR 2006;1623:294.
393. Kalliolias G, Antonopoulos L, Andonopoulos A, Liossis S. Beneficial effects of anakinra in patients with steriod-resistant adult onset Still's disease. ACR 2006;1624:295.
394. Fitzgerald AA, Leclercq SA, Yan A, Homik JE, Dinarello CA. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum 2005;52:1794-803.
395. Vasques Godinho FM, Parreira Santos MJ, Canas da SJ. Refractory adult onset Still's disease successfully treated with anakinra. Ann Rheum Dis 2005;64:647-8.
396. Antin JH, Weisdorf D, Neuberg D, Nicklow R, Clouthier S, Lee SJ, et al. Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood 2002;100:3479-82.
397. Birmingham J, Kraus V, Toth A. Clinical benefits of intra-articular anakinra (kineret) of knee signs and symptoms of injury, arthritis and arthrofibrosis. ACR 2006;F142(662).
398. Behrens EM, Kreiger PA, Cherian S, Cron RQ. Interleukin 1 receptor antagonist to treat cytophagic histiocytic panniculitis with secondary hemophagocytic lymphohistiocytosis. J Rheumatol 2006;33:2081-4.
399. Metyas S, Hoffman H. Anakinra prevents symptons of familial cold auto-inflammatory syndrome and Raynaud's disease. J Rheumatol 2006;33(10):1-3.
400. Bodar EJ, van der Hilst JC, Drenth JP, van der Meer JW, Simon A. Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model. Neth J Med 2005;63:260-4.
401. Rigante D, Ansuini V, Bertoni B, et al. Treatment with anakinra in the hyperimmunoglobulinemia D/periodic fever syndrome. Rheumatol Int 2006;27:97-100.
402. Verbsky JW, White AJ. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol 2004;31:2071-5.
403. Ilowite NT, Porras O, Reiff A, et al. A twelve-week open label safety and efficacy study of anakinra (KINERET) in juvenile rheumatoid arthritis. EULAR OP0071, 2003.
404. Ilowite NT, Reiff A, Rudge SR, Punaro MG, Martin J, et al. A randomized, multicenter, blinded, placebo-controlled study with an open-label run-in period to evaluate anakinra in polyarticular-course juvenile rheumatoid arthritis. [abstract] Arthritis & Rheum 2007;54:s327;723.
405. Hawkins P, Larchmann H. Interleukin-1-receptor antagonist in the Muckle Wells syndrome. N Engl J Med 2003;348:2583-4.
406. Saha M, Rustin M, Swale V, Hawkins P. Muckle-Wells syndrome successfully treated with an interleukin-1 receptor antagonist. Br J Dermatol 2004;151(Suppl 68):21-62.
407. Ramos E, Arostegui JI, Campuzano S, et al. Positive clinical and biochemical responses to anakinra in a 3-year-old patient with cryopyrin-associated periodic cyndrome (CAPS). Rheumatology 2005;44:1072-3.
408. Rynne M, Maclean C, Bybee A, McDermott MF, Emery P. Hearing improvement in a patient with variant Muckle-Wells syndrome in response to interleukin 1 receptor antagonism. Ann Rheum Dis 2006;65:533-4.
409. Mirault T, Launay D, Cuisset L, et al. Recovery form deafness in patients with muckle-wells syndrome treated with anakinra. Arthritis Rheum 2007;54:1697-700.
410. Goldbach-Mansky R, Daily N, Canna S, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1B inhabition. N Engl J Med 2007;355:581-92.
411. Frenkel J, Wulffraat N, Kuis W. Anakinra in mutation-negative NOMID/CINCA syndrome: comment on the articles by Hawkins et al and Hoffman and Patel. To the Editor. Arthtitis & Rheum 2007;50:3738-9.
412. Rigante D, Ansuini V, Calderelli M, et al. Hydrocephalus in CINCA syndrome treated with anakinra. Childs Nerv Syst 2006;22:334-7.
413. Seitz M, Kamgang RK, Simon HU, Villiger PM. Therapeutic interleukin (IL) 1 blockade normalises increased IL1 beta and decreased tumour necrosis factor alpha and IL10 production in blood mononuclear cells of a patient with CINCA syndrome. Ann Rheum Dis 2005;64:1802-3.
414. Granel B, Serratrice J, Disdier P, Weiller PJ. Dramatic improvement with anakinra in a case of chronic infantile neurological cutaneous and articular (CINCA) syndrome. Rheumatology 2005;44:689-90.
415. Namde M, Hill S, Duryea J, Plass N, Snyder C, et al. Arthropathy in patients with neonatal onset multisystem inflammatory disease (NOMID). Arthritis & Rheum 2006;54:s803;2046.
416. Namde M, Hildebrand P, Jain M, et al. Functional outcomes in neonatal onset multisystem inflammatory disease (NOMID) after 12 months of treatment with the recombinant IL-1 receptor antagonist anakinra. Ann Rheum Dis 2006;65(Suppl II):100.
417. Namde M, Canna S, Plass N, Rubin A, Kim J, Snyder B, et al. Twelve months after treating children with neonatal onset multisystem inflammatory disease (NOMID/CINCA) with the IL-1 receptor antagonist anakinra. Ann Rheum Dis 2006;65(Suppl II):448.
418. Gattorno M, Ferlito F, Pelogatti MA, et al. Clinical and biological effects of treatment with anakinra in CINCA syndrome and in systemic onset JIA. Ann Rheum Dis 2006;65(Suppl II):252.
419. Caroli F, Pontillo A, D'Osualdo A, Travan L, Ceccherini I, Crovella S, et al. Clinical and genetic characterization of Italian patients affected by CINCA syndrome. Rheumatology (Oxford) 2007;46:473-8.
420. Lovell DJ, Bowyer SL, Solinger AM. Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease. Arthritis Rheum 2005;52:1283-6.
421. Dierselhuis MP, Frenkel J, Wulffraat NM, Boelens JJ. Anakinra for flares of pyogenic arthritis in PAPA syndrome. Rheumatology (Oxford) 2005;44:406-8.
422. Jung N, Hoheisel R, Haase I, et al. Anakinra (IL1-RA) in the treatment of patients with active psoriatic arthritis refractory to or intolerant of methotrexate (MTX). Ann Rheum Dis 2005;64(Suppl 3):1092.
423. Gibbs A, Gogarty M, Bresnihan B, et al. Moderate clinical response and absence of MRI or immunohistological change suggest that anakinra is ineffective in psoriatic arthritis. ACR 2006;1809:481.
424. Vounotrypidis P, Sakellariou GT, Zisopoulos D, Berberidis C Refractory relapsing polychondritis:rapid and sustained response in the treatment with an IL-1 receptor antagonist (anakinra). Rheumatology 2006;45:491-2.
425. Martinez-Toboada V, Fontalba A, Blanco R, Fernandez-Luna J. Successful treatment of refractory Schnitzler Syndrome with anakinra: comment on the article by Hawkins et al. Arthritis Rheum 2005;52:2226-8.
426. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005;201:1479-86.
427. Henrickson M. Sustained efficacy of anakinra in refractory systemic arthritis failing etanercept. Arthritis & Rheum 2005;52:s83;131.
428. Reiff A. The use of anakinra in juvenile arthritis. Curr Rheumatol Rep 2005;7:434-40.
429. Mirkinson L, Nagle D, Jones O, Kadom N. Anakinra therapy in a child with systemic-onset juvenile rheumatoid arthritis after human herpesvirus 6 encephalitis. J Clin Rheumatol 2006;12:83-6.
430. Weiss J, Henrickson M, Walco G, Feinstein A, Kimura Y, Sanzari J, et al. Combination therapy with anakinra and anti-TNF agents in refractory systemic JIA (SJIA). Pediatric Rheumatology, Pres 2007;134.
431. Punaro L, Allantaz F, Stichweh D, Pascual V. Clinical and microarray follow-up of systemic onset juvenile idiopathic arthritis patients threated with anakinra. OASIS 2007;616.
432. Zeft A, Schlesinger M, Bohnsack J. Anakinra in systemic juvenile idiopathic arthritis: The Intermountain West Experience. ACR 2006;1704:375.
433. Gattorno M, Ferlito F, Pelagatti MA, et al. Patterns of IL-1 B secretion and response to anti-IL-1 treatment in Cias-1 mutated patients and systemic onset JIA (soJIA). ACR 2006;2115.
434. Strand V, Balbir GA, Pavelka K, et al. Sustained benefit in rheumatoid arthritis following one course of rituximab: improvements in physical function over 2 years. Rheumatology (Oxford) 2006:1-9.
435. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81.
436. Popa C, Leandro MJ, Cambridge G, et al. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 years. Rheumatology (Oxford) 2007:1-5.
437. Higashida J, Wun T, Schmidt S. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor treatment. J Rheumatol 2005;32:2109-15.
438. Moore J, Ma D, Will R, et al. A phase II study of rituximab in rheumatoid arthritis patients with recurrent disease following haematopoietic stem cell transplantation Bone Marrow Transplant 2004;34:241-7.
439. Kneitz C, Wilhelm M, Tony HP. Improvement of refractory rheumatoid arthritis after depletion of B cells. Scand J Rheumatol 2007;33:82-6.
440. Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 2002;61:883-8.
441. De Vita S, Zaja F, Sacco S, et al. Efficacy of selective B cell blockage in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum 2007;46:2029-33.
442. Scheinberg M, Hamerschlak N, Kutner JM, et al. Rituximab in refractory autioimmune diseases: Brazilian experience with 29 patients (2002-2004). Clin Exp Rheumatol 2002;24:65-9.
443. Maher L, Wilson JG. Successful treatment of rheumatoid vasculitis-associated foot drop with rituximab. Rheumatology (Oxford) 2006;45:1450-1.
444. Cambridge G, Stohl W, Leandro MJ. Circulating levels of B lymphocyte simulator in patients with rheumatiod arthritis following rituximab treatment. Arthritis Rheum 2006;54:723-32.
445. Leandro MJ, Cambridge G, Ehrensten M, et al. Reconstitution of peripheral blook B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:613-20.
446. Roll P, Palanichamy A, Kneitz C, et al. Regeneration of B cell subsets after transient B cell depletion unsing anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 2007;54:2377-86.
447. Stasi R, Stipa E, Del Poeta G, et al. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford) 2006;45:1432-6.
448. Ericksson P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitus successfully treated with rituximab. J Intern Med 2005;257:540-8.
449. Smith KGC, Jones RB, Burns SM, et al. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitus. Arthritis Rheum 2006;54:2970-82.
450. Aries PM, Hellmich B, Voswinkel J, et al. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory grandulomatous manifestations. Ann Rheum Dis 2006;65:853-8.
451. Keogh KA, Ytterberg SR, Fervenza FC, et al. Rituximab for refractory Wegener's granulomatosis: report of a prospective, one-label pilot trial. Am J Respir Crit Care Med 2007;173:180-7.
452. Sanchez-Cano D, Callejas-Rubio JL, Rios-Fernandez R, et al. Use of rituximab in Wegener's granulomatosis: comment on the article by Wong. Nephrol Dial Transplant 2007;22:958-9.
453. Tektonidou MG, Skopouli FN. Sustained 3-year remission aftr rituximab treatment in a patient with refractory Wegener's granulomatosis. Clin Exp Rheumatol 2006;24:S103.
454. Bachmeyer C. Rituximab is an alternative in a case of contra-indication of cyclophosphamide with Wegener's granulomatosis. Nephrol Dial Transplant 2005;20:1274.
455. Ferraro AJ, Day G, Drayson MT, et al. Effective thearpeutic use of Rituximab in refractory Wegener's granulomatosis. Nephrol Dial Transplant 2005;20:622-5.
456. Kallenbach M, Duan H, Ring T. Rituximab induced remission in a patient with Wegener's granulomatosis. Nephron Clin Pract 2005;99:c92-6.
457. Memet B, Rudinskaya A, Kerbs T, et al. Wegener's granulomatosis with massive intracerebral hemorrhage. J Clin Rheumatol 2005;11:318.
458. Specks U, Fervensa, McDonald TJ, et al. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2007;44:2840.
459. Clatworthy MR, Jayne DRW. Acquired hemophilia in association with ANCA-associated vasculitis: response to rituximab. Am J Kidney Dis 2006;47:680-2.
460. Koukoulaki M, Smith KGC, Jayne DRW. Rituximab in Churg-Strauss syndrome. Ann Rheum Dis 2006;65:557-9.
461. Kaushik V, Reddy HV, Bucknall RC. Successful use of rituximab in a patient with recalcitrant Churg-Strauss symdrome. Ann Rheum Dis 2006;65:1116-7.
462. Sansonno D, De Re V, Lauletta G. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 2003;101:3818-26.
463. Quartuccio L, Soardo G, Romano G, et al. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. Rheumatology (Oxford) 2007;45:824-46.
464. Bassee G, Ribes D, Kamar N, et al. Rituximab therapy for mixed cryoglobulinemia in seven renal transplant patients. Transplant Proc 2007;38:2308-10.
465. Cai FZJ, Ahern M, Smith M. Treatment of cryoglobluinemia associated peripheral neuropathy with rituximab. J Rheumatol 2006;33:1197-8.
466. Pekow J, Chung RT. Treatment of type II cryoglobulinemia associated with hepatitis C with rituximab. J Clin Gastroenterol 2006;40:450.
467. Telander DG, Hollander G, Wax MB, et al. Rubeosis and anterior segment ischemia associated with systemic cryoglobulinemia. Am J Ophthalmol 2006;142:689.
468. Bryce AH, Kyle RA, Dispenzieri A, et al. Response to rituximab in patients with type II cryoglobulinemia. Clin Lymphoma Myeloma 2007;7:140-4.
469. Zaja F, De Vita S, Massaro C, et al. Efficacy and safety of fituximab in type II mixed cryoglobulinemia. Blood 2003;101:3827- 34.
470. Arzoo K, Sadeghi S, Liebman HA. Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). Ann Rheum Dis 2002;61:922-4.
471. Basse G, Ribes D, Kamar N, et al. Rituximab therapy for de novo mixed cryoglobulinemia in renal transplant patients. Transportation 2005;82:1560-4.
472. Ghijsels E, Lerut E, Vanrenterghem Y, et al. Anti-CD20 monoclonal antibody (rituximab) treatment for hepatitis C-negative therapy-resistant essential mixed cryoglobulinemia with renal and cardiac failure. Am J Kidney Dis 2004;43:e34-8.
473. Lamprecht P, Lerin-Lozano C, Merz H, et al. Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis. Ann Rheum Dis 2003;62:1230-3.
474. Bryce AH, Kyle RA, Dispenzieri A, et al. Natural history and therapy of 66 patients with mixed cryoglobulinemia. Am J Hematol 2007;81:511-8.
475. Nehme SH, Korganow AS, Pasquail JL, et al. Rituximab inefficiency during type I cryoglobulinaemin. Rheumatology (Oxford) 2005;44:410-1.
476. Ring T, Kallenbach M, Praetorius J, et al. Successful treatment of a patient with primary Sjogren's syndrome with rituximab. Clin Rheumatol 2006;25:891-4.
477. Touma Z, Sayad J, Arayssi T. Successful treatment of Sjogren's syndrome with rituximab. Scand J Rheumatol 2006;35:323-5.
478. Pijpe J, Van-Imhoff GW, Spijkervet FKL, et al. Rituximab treatment in patients with primary Sjogren's syndrome. Arthritis Rheum 2005;52:2740-50.
479. Pijpe J, Van-Imhoff GW, Vissink A, et al. Changes in salivary gland immunohistology and function after rutiximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma. Ann Rheum Dis 2005;65:958-60.
480. Voulgarelis M, Giannouli S, Tzioufas AG, Moutsopoulos HM. Long term remission of Sjogren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Ann Rheum Dis 2006;65:1033-7.
481. Voulgarelis M, Giannouli S, Anagnostou D, et al. Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjogren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas. Rheumatology (Oxford) 2004;43:1050-3.
482. Gottenberg JE, Guillevin L, Lambotte O, et al. Tolerance and short-term efficacy of rituximcib in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005;64:913-20.
483. Ahmadi-Simab K, Lamprecht P, Nolle B, et al. Successful treatment of refractory anterior scleritis in primary Sjogren's syndrome with rituximab. Ann Rheum Dis 2005;64:1087-8.
484. Harner KC, Jackson LW, Drabick JJ. Normalization of anticardiolipin antibodies following rituximab therapy for marginal zone lymphoma in a patient with Sjogren's syndrome. Rheumatology (Oxford) 2004;43:1309-10.
485. Somer GB, Tsai DE, Downs L, et al. Improvement in Sjogren's syndrome following therapy with rituximab for marginal zone lymphoma. Arthritis Rheum 2003;49:394-8.
486. Shih WJ, Ghesani N, Hongming Z, et al. F-18 FDG positron emission tomography demonstrates resolution of non-Hodgkin's lymphoma of the parotid gland in a patient with Sjogren's syndrome: before and after anti-CD20 antibody rituximab therapy. Clin Nucl Med 2002;27:142-3.
487. Ramos-Casals M, Lopex-Guillermo A, Brito-Zeron P, et al. SS-HCV Study Group. Treatment of B-cell lymphoma with rituximab in two patients with Sjogren's syndrome associated with hepatitis C virus infection. Lupus 2004;13:969-71.
488. Kuek A, Hazleman BL, Gaston JH, et al. Successful treatment of refractory polyarticular juvenile idiopathic arthritis with rituximab. Rheumatology (Oxford) 2006;45:1448-9.
489. Kelaidi C, Tulliez M, Lecoq-Lafon C, et al. Long-term remission of an EBV-positive B cell lymphoproliferative disorder associated with rheumatoid arthritis under methotrexate with anti-CD20 monoclonal antibody (rituximab) monotherapy. Leukemia 2002;16:2173-4.
490. Armstrong DJ, McCarron MT, Wright GD. SLE-associated transverse myelitis successfully treated with Rituximab (anti-CD20 monoclonal antibody). Rheumatol Int 2006;26:772.
491. Gomard-Mennesson E, Ruivard M, Koenig M, et al. Treatment of isolated severe immune hemolytic anaemia associated with systemic lupus erythematosus: 26 cases. Lupus 2006;15:223-31.
492. Haddad E, Willems M, Niaudet P, et al. Rituximab therapy for childhood-onset systemic lupus erythematosus. J Rheumatol 2006;33:390.
493. Janssen AF, Wintergerst U, Renner ED, et al. Rituximab-induced long-term remission in two children with SLE. Eur J Pediatr 2007;166:177-81.
494. Kotani T, Takeuchi T, Kawasaki Y, et al. Successful treatment of cold agglutinin disease with anti-CD20 antibody (rituximab) in a patient with systemic lupus erythematosus. Lupus 2006;15:683-5.
495. MacDermott EJ, Lehman TJA. Prospective, open-label trial of rituximab in childhood systemic lupus erythematosus. Curr Rheumatol Rep 2006;8:439-11.
496. Marks SD, Tullus K. Successful outcomes with rituximab therapy for refractory childhood systemic lupus erythematosus. Pediatr Nephrol 2006;21:598-9.
497. Ng KP, Leandro MJ, Edwards JC, et al. Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. Ann Rheum Dis 2007;65:942-5.
498. Rech J, Hueber AJ, Kallert S, et al. Immunoadsorption and CD20 antibody treatment in a patient with treatment resistant systemic lupus erythematosus and preterminal renal insufficiency. Ann Rheum Dis 2006;65:552-3.
499. Risselada AP, Kallenberg CGM. Therapy-resistent lupus skin disease successfully treated with rituximab. Rheumatology (Oxford) 2006;45:915-6.
500. Tokunaga M, Saifo K, Kawabata D, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 2007;66:470-5.
501. Leandro MJ, Cambridge G, Edwards JC. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 2005;44:1542-5.
502. Leandro MJ, Edwards JC, Cambridge G, et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002;46:2677.
503. Anolik JH, Barnard J, Cappione A, et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004;50:3580-90.
504. Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004;50:2580- 9.
505. Anolik JH, Campbell D, Felgar RE, et al. The relationship of FcãRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003;48:455-9.
506. Tokunaga M, Fujii K, Saito K, et al. Down-regulation of CD40 and CD80 on B cells in patients with life- threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology (Oxford) 2005;44:176-82.
507. Edelbauer M, Jungraithmayr T, Zimmerhackl LB. Rituximab in childhood systemic lupus erythematosus refractory to conventional immunosuppression. Pediatr Nephrol 2005;20:811-3.
508. Carroll RP, Brown F, Kerr PG. Anti CD20 antibody treatment in refractory class IV lupus nephritis. Nephrol Dial Transplant 2007;22:291-3.
509. Jacobson SH, van VR, Gunnarsson I, et al. Rituximab-induced long-term remission of membranous lupus nephritis. Nephrol Dial Transplant 2006;21:1742-3.
510. Vigna PM, Hernandez CB, Paredes SO, et al. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 2006;8:1-9.
511. Ahn ER, Lander G, Bidot CJ, et al. Long-term remission from life-threatening hypercoagulable state associated with lupus anticoagulant (LA) following rituximab therapy. Am J Hematol 2005;78:127-9.
512. Ames PRJ, Tommasino C, Fossati G. Limited effect of rituximab on thrombocytopenia and anticardiolipin antibodies in a patient with primary antiphospholipid syndrome. Ann Hematol 2007;86:227-8.
513. Trappe R, Lowe A, Thuss PP, et al. Successful treatment of thrombocytopenia in primary antiphospholipid antibody syndrome with the anti-CD20 antibody rituximab-monitoring of antiphospholipid and anti-GP antibodies: a case report. Ann Hematol 2006;85:134-5.
514. Veneri D, Ambrosetti A, Franchini M, et al. Remission of severe antiphospholipid syndrome associated with non-Hodgkin's B-cell lymphoma after combined treatment with rituximab and chemotherapy. Haematologica 2005;90:15-6.
515. Rubenstein J, Arkfeld DG, Metyas S, et al. Rituximab treatment for resistant antiphospholipid syndrome. J Rheumatol 2006;33:355-7.
516. Arlet JB, Dimitri D, Pagnoux C, et al. Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP). Neuromuscul Discord 2006;16:334-6.
517. Brulhart L, Waldburger JM, Gabay C. Rituximab in the treatment of antisynthetase syndrome. Ann Rheum Dis 2006;65:974-5.
518. Dinh HV, McCormic C, Hall S, Prince HM. Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases. J Am Acad Dermatol 2007;56:148-53.
519. Lambotte O, Kotb R, Maigne G, et al. Efficacy of rituximab in refractory polymyositis. J Rheumatol 2005;32:1369-70.
520. Chung L, Genovese MC, Fiorentino D. Rituximab in the treatment of patients with dermatomyositis: 12 week interim analysis of a pilot trial. Arthritis Rheum 2005;52:4088.
521. Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005;52:601-7.
522. Noss EH, Hausner-Sypek DL, Weinblatt ME. Rituximab for refractory polymyositis and dermatomyositis. J Rheumatol 2007;33:1021-6.
523. Ahnadi SK, Lamprecht P, Jankowiak C. Successful treatment of refractory adult onset Still's disease with rituximab. Ann Rheum Dis 2006;65:1117-8.